Skip to main content
Top
Published in: Gastric Cancer 5/2023

29-05-2023 | Gastric Cancer | Original Article

Oncological impact of unexpected horizontal tumor spread in gastric cancer that requires total gastrectomy

Authors: Yasufumi Koterazawa, Manabu Ohashi, Masaru Hayami, Rie Makuuchi, Satoshi Ida, Koshi Kumagai, Takeshi Sano, Souya Nunobe

Published in: Gastric Cancer | Issue 5/2023

Login to get access

Abstract

Background

Gastric cancer often exhibits discrepancies between the gross and pathological tumor boundaries, and the degree of discrepancy may be a tumor characteristic. However, whether these discrepancies influence oncological outcomes remains unclear.

Methods

The data of patients who underwent total gastrectomy for gastric cancer from 2005 to 2018 were collected. A new parameter, ΔPM, which corresponds to the length of the discrepancy between the gross and pathological proximal boundaries, was calculated and the patients were divided into two groups: patients with long ΔPM and those with short ΔPM. Oncological outcomes were compared between the two groups.

Results

A length of 8 mm was determined as the cutoff value for long or short ΔPM. Tumor size, growth pattern, pathological type, depth, and esophageal invasion were associated with ΔPM > 8 mm. Overall survival of the ΔPM > 8 mm group was significantly worse than that of the ΔPM ≤ 8 mm group (5-year overall survival: 58% vs 78%; p < 0.0001). Multivariate analysis revealed that ΔPM > 8 mm was an independent risk factor for poor survival and peritoneal metastasis. The likelihood ratio test revealed a significant interaction between pT status and ΔPM (p = 0.0007). Circumferential involvement and gross esophageal invasion were poorer survival factors in the ΔPM > 8 mm group.

Conclusions

ΔPM > 8 mm is related to several clinicopathological characteristics and is an independent risk factor for poorer survival and peritoneal metastasis but not local recurrence. ΔPM > 8 mm combined with circumferential involvement or esophageal invasion is associated with relatively poor survival outcomes.
Appendix
Available only for authorised users
Literature
1.
go back to reference Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.CrossRefPubMed Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.CrossRefPubMed
2.
go back to reference Bozzetti F, Bonfanti G, Bufalino R, Menotti V, Persano S, Andreola S, Doci R, Gennari L. Adequacy of margins of resection in gastrectomy for cancer. Ann Surg. 1982;196:682–90.CrossRef Bozzetti F, Bonfanti G, Bufalino R, Menotti V, Persano S, Andreola S, Doci R, Gennari L. Adequacy of margins of resection in gastrectomy for cancer. Ann Surg. 1982;196:682–90.CrossRef
3.
go back to reference Ha TK, Kwon SJ. Clinical importance of the resection margin distance in gastric cancer patients. J Korean Gastric Cancer Assoc. 2006;6:277–83.CrossRef Ha TK, Kwon SJ. Clinical importance of the resection margin distance in gastric cancer patients. J Korean Gastric Cancer Assoc. 2006;6:277–83.CrossRef
4.
go back to reference Bissolati M, Desio M, Rosa F, Rausei S, Chiari D, Molfino S, et al. Risk factor analysis for involvement of resection margins in gastric and esophagogastric junction cancer: an Italian multicenter study. Gastric Cancer. 2017;20:70–82.CrossRefPubMed Bissolati M, Desio M, Rosa F, Rausei S, Chiari D, Molfino S, et al. Risk factor analysis for involvement of resection margins in gastric and esophagogastric junction cancer: an Italian multicenter study. Gastric Cancer. 2017;20:70–82.CrossRefPubMed
5.
go back to reference Hallissey MT, Jewkes AJ, Dunn JA, Ward L, Fielding JW, et al. Resection-line involvement after gastric cancer: a continuing problem. Br J Surg. 1993;80:1418–20.CrossRefPubMed Hallissey MT, Jewkes AJ, Dunn JA, Ward L, Fielding JW, et al. Resection-line involvement after gastric cancer: a continuing problem. Br J Surg. 1993;80:1418–20.CrossRefPubMed
6.
go back to reference Bickenbach KA, Gonen M, Strong V, Brennan MF, Coit DG. Association of positive transection margins with gastric cancer survival and local recurrence. Ann Surg Oncol. 2013;20:2663–8.CrossRefPubMed Bickenbach KA, Gonen M, Strong V, Brennan MF, Coit DG. Association of positive transection margins with gastric cancer survival and local recurrence. Ann Surg Oncol. 2013;20:2663–8.CrossRefPubMed
7.
go back to reference Morgagni P, Garcea D, Marrelli D, De Manzoni G, Natalini G, Kurihara H, et al. Resection line involvement after gastric cancer surgery: clinical outcome in nonsurgically retreated patients. World J Surg. 2008;32:2661–7.CrossRefPubMed Morgagni P, Garcea D, Marrelli D, De Manzoni G, Natalini G, Kurihara H, et al. Resection line involvement after gastric cancer surgery: clinical outcome in nonsurgically retreated patients. World J Surg. 2008;32:2661–7.CrossRefPubMed
8.
go back to reference Hayami M, Ohashi M, Kumagai K, Sano T, Hiki N, Nunobe S, et al. A “Just Enough” gross proximal margin length ensuring pathologically complete resection in distal gastrectomy for gastric cancer. Ann Surg. 2020;1(2):pe026.CrossRef Hayami M, Ohashi M, Kumagai K, Sano T, Hiki N, Nunobe S, et al. A “Just Enough” gross proximal margin length ensuring pathologically complete resection in distal gastrectomy for gastric cancer. Ann Surg. 2020;1(2):pe026.CrossRef
9.
go back to reference Koterazawa Y, Ohashi M, Hayami S, Kumagai K, Sano T, Nunobe S, et al. Minimum esophageal resection length to ensure negative proximal margin in total gastrectomy for gastric cancer. Ann Surg Open. 2022;3(1):pe127.CrossRef Koterazawa Y, Ohashi M, Hayami S, Kumagai K, Sano T, Nunobe S, et al. Minimum esophageal resection length to ensure negative proximal margin in total gastrectomy for gastric cancer. Ann Surg Open. 2022;3(1):pe127.CrossRef
10.
go back to reference Koterazawa Y, Ohashi M, Hayami M, Makuuchi R, Ida S, Kumagai K, et al. Required esophageal resection length beyond the tumor boundary to ensure a negative proximal margin for gastric cancer with gross esophageal invasion or esophagogastric junction cancer. Gastric Cancer. 2023;26:451–9 (Epub ahead of print). CrossRefPubMed Koterazawa Y, Ohashi M, Hayami M, Makuuchi R, Ida S, Kumagai K, et al. Required esophageal resection length beyond the tumor boundary to ensure a negative proximal margin for gastric cancer with gross esophageal invasion or esophagogastric junction cancer. Gastric Cancer. 2023;26:451–9 (Epub ahead of print). CrossRefPubMed
11.
go back to reference Muneoka Y, Ohashi M, Ishizuka N, Hayami M, Makuuchi R, Ida S, et al. Risk factors and oncological impact of positive resection margins in gastrectomy for cancer: are they salvaged by an additional resection? Gastric Cancer. 2022;25:287–96.CrossRefPubMed Muneoka Y, Ohashi M, Ishizuka N, Hayami M, Makuuchi R, Ida S, et al. Risk factors and oncological impact of positive resection margins in gastrectomy for cancer: are they salvaged by an additional resection? Gastric Cancer. 2022;25:287–96.CrossRefPubMed
12.
go back to reference Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;14:101–12.CrossRef Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;14:101–12.CrossRef
13.
go back to reference Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2018 (ver. 5). Gastric Cancer. 2021;24:1–21.CrossRef Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2018 (ver. 5). Gastric Cancer. 2021;24:1–21.CrossRef
14.
go back to reference Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810–20.CrossRefPubMed Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810–20.CrossRefPubMed
15.
go back to reference Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, CLASSIC trial investigators, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379:315–21.CrossRefPubMed Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, CLASSIC trial investigators, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379:315–21.CrossRefPubMed
16.
go back to reference Yoshida K, Kodera Y, Kochi M, Ichikawa W, Kakeji Y, Sano T, et al. Addition of docetaxel to oral fluoropyrimidine improves efficacy in patients with stage III gastric cancer: interim analysis of JACCRO GC-07, a randomized controlled trial. J Clin Oncol. 2019;37:1296–304.CrossRefPubMedPubMedCentral Yoshida K, Kodera Y, Kochi M, Ichikawa W, Kakeji Y, Sano T, et al. Addition of docetaxel to oral fluoropyrimidine improves efficacy in patients with stage III gastric cancer: interim analysis of JACCRO GC-07, a randomized controlled trial. J Clin Oncol. 2019;37:1296–304.CrossRefPubMedPubMedCentral
17.
go back to reference Wang SY, Yeh CN, Lee HL, Liu YY, Chao TC, Hwang TL, et al. Clinical impact of positive surgical margin status on gastric cancer patients undergoing gastrectomy. Ann Surg Oncol. 2009;16:2738–43.CrossRefPubMed Wang SY, Yeh CN, Lee HL, Liu YY, Chao TC, Hwang TL, et al. Clinical impact of positive surgical margin status on gastric cancer patients undergoing gastrectomy. Ann Surg Oncol. 2009;16:2738–43.CrossRefPubMed
18.
go back to reference Stiekema J, Cats A, Kuijpers A, Coevorden F, Boot H, Jansen EP, et al. Surgical treatment results of intestinal and diffuse type gastric cancer. Implications for a differentiated therapeutic approach? Eur J Surg Oncol. 2013;39:686–93.CrossRefPubMed Stiekema J, Cats A, Kuijpers A, Coevorden F, Boot H, Jansen EP, et al. Surgical treatment results of intestinal and diffuse type gastric cancer. Implications for a differentiated therapeutic approach? Eur J Surg Oncol. 2013;39:686–93.CrossRefPubMed
19.
go back to reference Blackham AU, Swords DS, Levine EA, Fino NF, Squires MH, Poultsides G, et al. Is linitis plastic a contraindication for surgical resection: a multi-institution study of the U.S. Gastric Cancer Collaborative. Ann Surg Oncol. 2016;23:1203–11.CrossRefPubMed Blackham AU, Swords DS, Levine EA, Fino NF, Squires MH, Poultsides G, et al. Is linitis plastic a contraindication for surgical resection: a multi-institution study of the U.S. Gastric Cancer Collaborative. Ann Surg Oncol. 2016;23:1203–11.CrossRefPubMed
20.
go back to reference Squires MH 3rd, Kooby DA, Poultsides GA, Pawlik TM, Saunders N, Jin LX, et al. Is it time to abandon the 5-cm margin rule during resection of distal gastric adenocarcinoma? A multi-institution study of the U.S. Gastric Cancer Collaborative. Ann Surg Oncol. 2015;22:1243–51.CrossRefPubMed Squires MH 3rd, Kooby DA, Poultsides GA, Pawlik TM, Saunders N, Jin LX, et al. Is it time to abandon the 5-cm margin rule during resection of distal gastric adenocarcinoma? A multi-institution study of the U.S. Gastric Cancer Collaborative. Ann Surg Oncol. 2015;22:1243–51.CrossRefPubMed
21.
go back to reference Hayami M, Ohashi M, Ishizuka N, Hiki N, Kumagai K, Souya N, et al. Oncological impact of gross proximal margin length in distal gastrectomy for gastric cancer: is the Japanese recommendation valid? Ann Surg Open. 2021;2(1):pe036.CrossRef Hayami M, Ohashi M, Ishizuka N, Hiki N, Kumagai K, Souya N, et al. Oncological impact of gross proximal margin length in distal gastrectomy for gastric cancer: is the Japanese recommendation valid? Ann Surg Open. 2021;2(1):pe036.CrossRef
22.
go back to reference Berlth F, Kim WH, Choi JH, Park SH, Kong SH, Lee HJ, et al. Prognostic impact of frozen section investigation and extent of proximal safety margin in gastric cancer resection. Ann Surg. 2020;272:871–8.CrossRefPubMed Berlth F, Kim WH, Choi JH, Park SH, Kong SH, Lee HJ, et al. Prognostic impact of frozen section investigation and extent of proximal safety margin in gastric cancer resection. Ann Surg. 2020;272:871–8.CrossRefPubMed
23.
go back to reference Ohe H, Lee WY, Hong SW, Chang YG, Lee B. Prognostic value of the distance of proximal resection margin in patients who have undergone curative gastric cancer surgery. World J Surg Oncol. 2014;23(12):296.CrossRef Ohe H, Lee WY, Hong SW, Chang YG, Lee B. Prognostic value of the distance of proximal resection margin in patients who have undergone curative gastric cancer surgery. World J Surg Oncol. 2014;23(12):296.CrossRef
24.
go back to reference Kim MG, Lee JH, Ha TK, Kwon SJ. The distance of proximal resection margin dose not significantly influence on the prognosis of gastric cancer patients after curative resection. Ann Surg Treat Res. 2014;87:223–31.CrossRefPubMedPubMedCentral Kim MG, Lee JH, Ha TK, Kwon SJ. The distance of proximal resection margin dose not significantly influence on the prognosis of gastric cancer patients after curative resection. Ann Surg Treat Res. 2014;87:223–31.CrossRefPubMedPubMedCentral
Metadata
Title
Oncological impact of unexpected horizontal tumor spread in gastric cancer that requires total gastrectomy
Authors
Yasufumi Koterazawa
Manabu Ohashi
Masaru Hayami
Rie Makuuchi
Satoshi Ida
Koshi Kumagai
Takeshi Sano
Souya Nunobe
Publication date
29-05-2023
Publisher
Springer Nature Singapore
Published in
Gastric Cancer / Issue 5/2023
Print ISSN: 1436-3291
Electronic ISSN: 1436-3305
DOI
https://doi.org/10.1007/s10120-023-01401-5

Other articles of this Issue 5/2023

Gastric Cancer 5/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.